InMed Pharmaceuticals Inc.INMNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank72
5Y CAGR-7.7%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-7.7%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 35.80% |
| Q3 2025 | -50.09% |
| Q2 2025 | 130.95% |
| Q1 2025 | -14.46% |
| Q4 2024 | 9.26% |
| Q3 2024 | 17.13% |
| Q2 2024 | -11.66% |
| Q1 2024 | 0.74% |
| Q4 2023 | 5.02% |
| Q3 2023 | -30.44% |
| Q2 2023 | 41.36% |
| Q1 2023 | -33.41% |
| Q4 2022 | -7.98% |
| Q3 2022 | 30.48% |
| Q2 2022 | -9.52% |
| Q1 2022 | -21.40% |
| Q4 2021 | 69.18% |
| Q3 2021 | -12.07% |
| Q2 2021 | 17.06% |
| Q1 2021 | 38.99% |
| Q4 2020 | 53.58% |
| Q3 2020 | -18.63% |
| Q2 2020 | -14.90% |
| Q1 2020 | 3.50% |
| Q4 2019 | -1.78% |
| Q3 2019 | -39.37% |
| Q2 2019 | 4.01% |
| Q1 2019 | -1.43% |
| Q4 2018 | -17.52% |
| Q3 2018 | -5.36% |
| Q2 2018 | 50.16% |
| Q1 2018 | 39.51% |
| Q4 2017 | -23.27% |
| Q3 2017 | -2.94% |
| Q2 2017 | 51.03% |
| Q1 2017 | 39.52% |
| Q4 2016 | 95.38% |
| Q3 2016 | -14.77% |
| Q2 2016 | 37.35% |
| Q1 2016 | -42.31% |